These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
224 related items for PubMed ID: 8633501
1. Eosinophilia in primary biliary cirrhosis. Yamazaki K, Nakadate I, Suzuki K, Sato S, Masuda T. Am J Gastroenterol; 1996 Mar; 91(3):516-22. PubMed ID: 8633501 [Abstract] [Full Text] [Related]
2. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Yamazaki K, Suzuki K, Nakamura A, Sato S, Lindor KD, Batts KP, Tarara JE, Kephart GM, Kita H, Gleich GJ. Hepatology; 1999 Jul; 30(1):71-8. PubMed ID: 10385641 [Abstract] [Full Text] [Related]
3. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Nakamura A, Yamazaki K, Suzuki K, Sato S. Am J Gastroenterol; 1997 Dec; 92(12):2245-9. PubMed ID: 9399763 [Abstract] [Full Text] [Related]
4. [Eosinophilia in primary biliary cirrhosis: regression under therapy with ursodeoxycholic acid]. Wirth HP, Meyenberger C, Altorfer J, Ammann R, Blum HE. Schweiz Med Wochenschr; 1994 May 14; 124(19):810-5. PubMed ID: 8209204 [Abstract] [Full Text] [Related]
5. [Transient eosinophilia in primary biliary cirrhosis]. Wirth HP, Heer P, Bertschinger P, Meyenberger C, Ammann R, Altorfer J. Schweiz Med Wochenschr; 1993 Dec 04; 123(48):2278-83. PubMed ID: 8272802 [Abstract] [Full Text] [Related]
7. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR, Dutch PBC Study Group. Gastroenterology; 2009 Apr 04; 136(4):1281-7. PubMed ID: 19208346 [Abstract] [Full Text] [Related]
8. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon RE, Poupon R. Liver Int; 2004 Jun 04; 24(3):187-93. PubMed ID: 15189267 [Abstract] [Full Text] [Related]
9. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH. Liver Transpl; 2007 Sep 04; 13(9):1236-45. PubMed ID: 17763401 [Abstract] [Full Text] [Related]
10. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis. Simko V, Michael S, Prego V. Am J Gastroenterol; 1994 Mar 04; 89(3):392-8. PubMed ID: 8122652 [Abstract] [Full Text] [Related]
11. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. Hepatology; 2000 Dec 04; 32(6):1196-9. PubMed ID: 11093724 [Abstract] [Full Text] [Related]
12. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Chen L, Borozan I, Milkiewicz P, Sun J, Meng X, Coltescu C, Edwards AM, Ostrowski MA, Guindi M, Heathcote EJ, McGilvray ID. Liver Int; 2008 Aug 04; 28(7):997-1010. PubMed ID: 18422935 [Abstract] [Full Text] [Related]
13. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. Hepatology; 1996 Nov 04; 24(5):1098-103. PubMed ID: 8903382 [Abstract] [Full Text] [Related]
14. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate. Lee YM, Kaplan MM. Am J Gastroenterol; 2003 Jan 04; 98(1):205-8. PubMed ID: 12526960 [Abstract] [Full Text] [Related]
15. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Färkkilä M, Rautiainen H, Kärkkäinen P, Karvonen AL, Nurmi H, Niemelä O. Liver Int; 2008 Jul 04; 28(6):787-97. PubMed ID: 18397236 [Abstract] [Full Text] [Related]
16. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Hepatology; 2003 Jul 04; 38(1):196-202. PubMed ID: 12830002 [Abstract] [Full Text] [Related]
17. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Kim WR, Poterucha JJ, Jorgensen RA, Batts KP, Homburger HA, Dickson ER, Krom RA, Wiesner RH, Lindor KD. Hepatology; 1997 Jul 04; 26(1):22-6. PubMed ID: 9214447 [Abstract] [Full Text] [Related]
18. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Am J Gastroenterol; 2006 Jul 04; 101(7):1529-38. PubMed ID: 16863557 [Abstract] [Full Text] [Related]
19. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Batts KP, Jorgensen RA, Dickson ER, Lindor KD. Am J Gastroenterol; 1996 Nov 04; 91(11):2314-7. PubMed ID: 8931409 [Abstract] [Full Text] [Related]
20. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, Poupon RE, Poupon R. Hepatology; 2003 Jul 04; 38(1):203-9. PubMed ID: 12830003 [Abstract] [Full Text] [Related] Page: [Next] [New Search]